This study concerns quality of life in patients with myelofibrosis. Information about how myelofibrosis and its treatment affect the lives of patients is important to help doctors and patients make decisions about treatment. This study is being conducted by Dr. Murray Krahn, a scientist and professor at the University of Toronto and a general internist...Read More
From Time to time patients are asked to participate in market research for which there is remuneration. We fielded many questions from patients asking us what happens with this information and whether or not they should participate. Below is a link to a document we have created that should provide you with some guidance and...Read More
Satellite Symposium – December 7, 2012 Chronic Myeloid Leukemia (CML): Evaluating the Evolving Therapeutic Landscape to Improve Outcomes Speakers: Neil Shah, MD, PhD, University of California – San Francisco School of Medicine, San Francisco, CA, Paul J. Shami, MD, The University of Utah and Huntsman Cancer Institute, Salt Lake City, UT , Jorge E....Read More
The Issue: Although Canada has a relatively good Universal Healthcare program, this program is being eroded directly as a consequence of the high price of drugs and medicines used to treat patients. The Canadian Federal government has made a promise to put in place a National Pharmacare program that aligns with the goals of our...Read More
Disclaimer – This Website does not give medical advice All of the content is for general information and educational purposes only. The information posted on this website, or by the links provided by this website, are not to be used as substitute medical advice and or recommendations. Nothing on this site should be interpreted in...Read More
Thanks to our Friends Dr. Rob Rutledge and Dr. Timothy Walker for putting together this unique, over the internet ‘Skills for Healing’ workshop. What: The ‘Skills for Healing’ blood cancer day-long seminar / webcast. Learn about integrative medicine (combining conventional care with ways to empower body, mind and spirit), mindfulness-based stress reduction, cognitive reframing, meditation,...Read More
SPRYCEL (™) (dasatinib) SPRYCEL (dasatinib) has been issued marketing authorization with conditions for the treatment of adults with newly diagnosed Philadelphia chromosome positive (Ph+) chronic myeloid leukemia (CML) in chronic phase. SPRYCEL(TM) (dasatinib) has been issued marketing authorization without conditions for the treatment of adults with: Ph+ chronic, accelerated, or blast phase CML with resistance...Read More
Tasigna (™) (nilotinib) TASIGNA® is indicated for the treatment of adult patients with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase. TASIGNA® is also indicated for the treatment of chronic phase and accelerated phase Philadelphia chromosome positive chronic myeloid leukemia (CML) in adult patients resistant to or intolerant of at...Read More
TEVA-IMATINIB is indicated for the treatment of adult and pediatric patients with newly diagnosed Ph+ CML in chronic, accelerated or blast phase or after failure of interferon therapy. TEVA-IMATINIB is also indicated for use as a single agent for induction phase therapy in adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL)....Read More
Nulla vitae elit libero, a pharetra augue. Nulla vitae elit libero, a pharetra augue. Nulla vitae elit libero, a pharetra augue. Donec sed odio dui. Etiam porta sem malesuada.
